Friday, July 10, 2026

Drug profile · INN

dolutegravir, emtricitabine and tenofovir alafenamide

dolutegravir, emtricitabine and tenofovir alafenamide (DOLUTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — dolutegravir, emtricitabine and tenofovir alafenamide
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

dolutegravir, emtricitabine and tenofovir alafenamide (DOLUTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN dolutegravir, emtricitabine and tenofovir alafenamide
Brand DOLUTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE
Route ORAL
Formulation TABLET

Approval history

Authority Status Date
FDA approved

Frequently asked questions

What is dolutegravir, emtricitabine and tenofovir alafenamide?

dolutegravir, emtricitabine and tenofovir alafenamide (DOLUTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for dolutegravir, emtricitabine and tenofovir alafenamide?

DOLUTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE is a marketed brand name for dolutegravir, emtricitabine and tenofovir alafenamide. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of dolutegravir, emtricitabine and tenofovir alafenamide?

dolutegravir, emtricitabine and tenofovir alafenamide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.